Status:
UNKNOWN
A Real-World Patient-Reported Outcomes Study in Patients With Long-Term Use of Niraparib
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
This prospective, non-interventional study is designed to evaluate the quality of life of Chinese ovarian cancer patients with long-term niraparib use in a real-world setting. Participants will comple...
Detailed Description
In this prospective, non-interventional study, patients with platinum-sensitive relapsed ovarian cancer who have received niraparib as maintenance therapy for more than two years will agree to be cont...
Eligibility Criteria
Inclusion
- Age ≥18 years
- Histologically confirmed platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer
- Maintenance treatment with niraparib for ≥2 years and continuing for the next 28 days
- No significant cognitive impairment
- Understand the trial procedure and be able to sign the informed consent form before any study-related procedures
Exclusion
- Patients who are not suitable for participation in this study according to the investigator's evaluation
- Patients receiving antineoplastic drugs for other malignancies
- Patients who are unable to comply with the protocol procedures
Key Trial Info
Start Date :
August 23 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2024
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06037213
Start Date
August 23 2023
End Date
January 31 2024
Last Update
September 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100032